All Oncology News

Trials evaluate combined immunotherapy with stem cell transplant to combat hematologic malignancies.

Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.

Katherine Nathanson, MD, discusses how the genetics of BRCA1/2-associated tumors impacts tumor development in breast and ovarian cancer and response to treatment.

The FDA has extended its decision deadline by 3 months on a biologics license application for MYL-1401O, a trastuzumab biosimilar co-developed by Mylan and Biocon. A final decision is expected on or before December 3, 2017.

The FDA issued a historic approval of the first chimeric antigen receptor (CAR) T-cell therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

The FDA has granted a priority review to a supplemental new drug application for bosutinib for the first-line treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The investigational HER2-targeting antibody-drug conjugate DS-8201 has received an FDA breakthrough therapy designation for the treatment of patients with HER2-positive, locally advanced, or metastatic breast cancer.

Christine M. Lovly, MD, PhD, discusses the importance of identifying and targeting RET in non-small cell lung cancer.

Pembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.

David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.

The FDA has accepted a resubmitted new drug application for Lutathera (lutetium [177Lu] oxodotreotide) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

The FDA has granted a priority review to a supplemental biologics license application for obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with follicular lymphoma.

The European Commission has approved tivozanib for the treatment of patients with advanced renal cell carcinoma.

Gilead has announced plans to acquire Kite Pharma for $180.00 per share in cash, totaling approximately $11.9 billion.

The FDA has approved fulvestrant for use in hormone receptor-positive, HER2-negative locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.

Results from the PROSELICA trial showed that 20 mg/m2 of cabazitaxel (Jevtana) was as safe and effective as the 25 mg/m2 dose for postdocetaxel patients with metastatic castration-resistant prostate cancer.

Michael B. Atkins, MD, discusses the latest IMmotion150 findings and additional developments with immunotherapy in mRCC.

Results from the phase III ENDEAVOR trial showed that carfilzomib (Kyprolis) reduced the risk of death by 21% compared with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma

The guidelines provide evidence-based recommendations on staging, neoadjuvant and adjuvant chemotherapy, radical cystectomy, urinary diversion, perioperative surgical management, and pelvic lymphadenectomy.

The European Commission has approved the CDK 4/6 inhibitor ribociclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative locally advanced or metastatic breast cancer.

Prestigious National Cancer Institute (NCI) grant awarded for nearly $8 million to pursue unencumbered research on cancer progression.

The combination of frontline atezolizumab and bevacizumab demonstrated superior efficacy compared with sunitinib or atezolizumab monotherapy in patients with advanced renal cell carcinoma.

Hospice enrollment is low and use of aggressive treatment is high for elderly patients with acute myeloid leukemia, a situation investigators called “suboptimal” in results from a retrospective study.

Peter Black, MD, discusses the latest on durvalumab and other ongoing developments in the field of bladder cancer.

Francisco J. Esteva, MD, PhD, discusses the clinical implications of genomic testing for patients with metastatic breast cancer.

Antonia R. Sepulveda, MD, PhD, discusses the importance and utility of genetic testing in GI cancers, as well as noteworthy developments in microsatellite instability, BRAF, and KRAS testing in colorectal cancer.

Robert Andtbacka, MD, discusses the long-term results for T-VEC in melanoma and the remaining challenges with the oncolytic immunotherapy.

William J. Gradishar, MD, discusses the latest developments in the HER2-positive setting, as well as biomarker development and the potential for immunotherapy in breast cancer.

Ketan K. Badani, MD, discusses the benefits of robotic surgery in RCC and use of the technique among urologists.

Arsenic trioxide consolidation was effective and safe in newly diagnosed pediatric patients with acute promyelocytic leukemia, allowing a significant reduction in cumulative anthracycline doses